Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Université de Montréal

$105,000.00

Validation of biomarkers associated with the risk of developing diabetes as well as accelerated weight and lung function loss in a multinational prospective cystic fibrosis cohort

FY 2016-17

Summary
Cystic fibrosis (CF) is the most common fatal recessive genetic disease in Canada. Increased longevity due to aggressive treatments is however associated with the emergence of new complications, including cystic fibrosis-related diabetes (CFRD), with a prevalence of above 50% in patients over 30 years. CFRD is associated with a decline in weight and in pulmonary function, increasing the risk of mortality. In order to target patients needing more intensive monitoring and interventions, it is important to establish biomarkers that could predict the risk of CFRD and also the risk of accelerated clinical deterioration. Currently, CFRD is diagnosed using the 2-hour oral glucose tolerance test. Data obtained from our CF cohort in Montreal suggest that glucose and insulin values obtained at the first hour of this test would be good biomarkers because the values (high glucose and low insulin) are associated with a reduction in lung function and weight. These 2 key clinical parameters of the treatment of cystic fibrosis tend to decrease before CFRD diagnosis. To succeed, we will pool our data with a similar ongoing cohort that was established in 2010 in Lyon (France, Rhône-Alpes cohort), which includes more than 120 patients. These two cohorts will provide the largest CF cohort to study the risk of CFRD and relations between blood glucose and insulin levels as well as between lung function and weight. Because CFRD is a major complication accentuating the mortality, targeting patients at risk and establish biomarkers of clinical deterioration are priorities. Those biomarkers will then allow to test intervention studies to reduce glucose excursions, in addition to creating an international Francophone network to improve detection and prognosis of CFRD.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365514
Name
Boudreau Valérie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Validation of biomarkers associated with the risk of developing diabetes as well as accelerated weight and lung function loss in a multinational prospective cystic fibrosis cohort
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cystic Fibrosis; Diabetes; Glycemia; Insulin; Intermediate Time Points; Nutritional Status; Pulmonary Function; Weight
Abstract
Cystic fibrosis (CF) is the most common fatal recessive genetic disease in Canada. Increased longevity due to aggressive treatments is however associated with the emergence of new complications, including cystic fibrosis-related diabetes (CFRD), with a prevalence of above 50% in patients over 30 years. CFRD is associated with a decline in weight and in pulmonary function, increasing the risk of mortality. In order to target patients needing more intensive monitoring and interventions, it is important to establish biomarkers that could predict the risk of CFRD and also the risk of accelerated clinical deterioration. Currently, CFRD is diagnosed using the 2-hour oral glucose tolerance test. Data obtained from our CF cohort in Montreal suggest that glucose and insulin values obtained at the first hour of this test would be good biomarkers because the values (high glucose and low insulin) are associated with a reduction in lung function and weight. These 2 key clinical parameters of the treatment of cystic fibrosis tend to decrease before CFRD diagnosis. To succeed, we will pool our data with a similar ongoing cohort that was established in 2010 in Lyon (France, Rhône-Alpes cohort), which includes more than 120 patients. These two cohorts will provide the largest CF cohort to study the risk of CFRD and relations between blood glucose and insulin levels as well as between lung function and weight. Because CFRD is a major complication accentuating the mortality, targeting patients at risk and establish biomarkers of clinical deterioration are priorities. Those biomarkers will then allow to test intervention studies to reduce glucose excursions, in addition to creating an international Francophone network to improve detection and prognosis of CFRD.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Boudreau, Valérie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Université de Montréal - $105,000 Grant (2016-17) | Canada Spends